Compare Archer-Daniels-Midland Co (ADM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Revvity Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.71 (market cap $38.78B), while Revvity Inc trades at $117.64 (market cap $12.91B). The key difference: Archer-Daniels-Midland Co is far larger — about 3× Revvity Inc's market cap, and Archer-Daniels-Midland Co pays the higher dividend (2.59%). Which is the better fit depends on your goals.
| ADM | RVTY | |
|---|---|---|
Market Cap | $38.78B | $12.91B |
Sector | Consumer Staples | Technology |
52-Week High | $87.32 | $117.75 |
52-Week Low | $56.00 | $82.26 |
Enterprise Value | $47.03B | $15.23B |
Dividend Yield | 2.59% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $79.72, down 0.96% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows solid fundamentals with a P/E of 21.98 and P/S of 0.48, while revenue for 2025 was $80.27B. Recent news highlights growth in biofuels and crushing margins, with the company raising its 2026 earnings outlook after a strong Q2.
The outlook is positive, supported by raised guidance and operational strength, but risks include execution challenges and margin pressures. Analysts maintain a consensus price target of $88.00, indicating potential upside from current levels amid a predominantly hold rating sentiment.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
